Merck (MRK) Exceeds Market Returns: Some Facts to Consider

In the latest close session, Merck (MRK) was up +1.31% at $115.68. The stock's change was more than the S&P 500's daily gain of 1.15%. At the same time, the Dow added 1.38%, and the tech-heavy Nasdaq gained 1.38%.

Coming into today, shares of the pharmaceutical company had lost 6.61% in the past month. In that same time, the Medical sector lost 8.2%, while the S&P 500 lost 5.69%.

The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period.

MRK's full-year Zacks Consensus Estimates are calling for earnings of $5.47 per share and revenue of $66.68 billion. These results would represent year-over-year changes of -39.09% and +2.57%, respectively.

It is also important to note the recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.18% rise in the Zacks Consensus EPS estimate. Merck is currently sporting a Zacks Rank of #3 (Hold).

In terms of valuation, Merck is currently trading at a Forward P/E ratio of 20.89. This expresses a premium compared to the average Forward P/E of 14.11 of its industry.

We can additionally observe that MRK currently boasts a PEG ratio of 2.08. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 2.08 at the close of the market yesterday.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 176, finds itself in the bottom 29% echelons of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research